



Crizotinib (Xalkori®)

Lungenkarzinom, nicht-kleinzellig (NSCLC) » ALK+ » ab
Zweitlinientherapie

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

Herausgeber

DGHO Deutsche Gesellschaft für Hämatologie und
Medizinische Onkologie e.V.
Bauhofstr. 12
10117 Berlin

Geschäftsführende Vorsitzende: Prof. Dr. med. Claudia Baldus

Telefon: +49 (0)30 27 87 60 89 - 0

info@dgho.de

www.dgho.de

Ansprechpartner

Prof. Dr. med. Bernhard Wörmann
Medizinischer Leiter

Quelle

www.onkopedia.com

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

Inhaltsverzeichnis

1 Crizotinib, NSCLC, ALK+, second line	2
---	----------

Crizotinib (Xalkori®)

Dokument: Fact Sheet

Spezifizierung: Lungenkarzinom, nicht-kleinzellig (NSCLC) » ALK+ » ab Zweitlinientherapie

Stand: Juli 2021

1 Crizotinib, NSCLC, ALK+, second line

Crizotinib, NSCLC, ALK+, second line

onkopedia				Facts	Appraisal	EU Approval 2012																																																																															
Parameter	Results¹⁴	HR¹⁵	p value	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 10%;">5</td><td style="width: 10%;">4</td><td style="width: 10%;">3b</td><td style="width: 10%;">3a</td><td style="width: 10%;">2c</td><td style="width: 10%;">2b</td><td style="width: 10%;">2a</td><td style="width: 10%;">1b</td><td style="width: 10%;">1a</td> </tr> <tr> <td colspan="9">Evidence (LoE)</td> </tr> <tr> <td colspan="9" style="text-align: center;"> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;">1</td><td style="width: 20%;">2</td><td style="width: 20%;">3</td><td style="width: 20%;">4</td><td style="width: 20%;">5</td> </tr> <tr> <td colspan="5">Clinical benefit (ESMO MCBS)</td> </tr> </table> </td> </tr> <tr> <td colspan="9"> <div style="display: flex; justify-content: space-around;"> ■ curative ■ non-curative </div> </td> </tr> <tr> <td colspan="9"> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;">lower</td><td style="width: 20%;">not proven</td><td style="width: 20%;">not quantifiable</td><td style="width: 20%;">minor</td><td style="width: 20%;">considerable</td><td style="width: 20%;">major</td> </tr> <tr> <td colspan="6">Additional benefit (G-BA)</td> </tr> <tr> <td colspan="6">suitable for chemotherapy</td> </tr> <tr> <td colspan="6">not suitable for chemotherapy</td> </tr> </table> </td> </tr> </table>			5	4	3b	3a	2c	2b	2a	1b	1a	Evidence (LoE)									<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;">1</td><td style="width: 20%;">2</td><td style="width: 20%;">3</td><td style="width: 20%;">4</td><td style="width: 20%;">5</td> </tr> <tr> <td colspan="5">Clinical benefit (ESMO MCBS)</td> </tr> </table>									1	2	3	4	5	Clinical benefit (ESMO MCBS)					<div style="display: flex; justify-content: space-around;"> ■ curative ■ non-curative </div>									<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;">lower</td><td style="width: 20%;">not proven</td><td style="width: 20%;">not quantifiable</td><td style="width: 20%;">minor</td><td style="width: 20%;">considerable</td><td style="width: 20%;">major</td> </tr> <tr> <td colspan="6">Additional benefit (G-BA)</td> </tr> <tr> <td colspan="6">suitable for chemotherapy</td> </tr> <tr> <td colspan="6">not suitable for chemotherapy</td> </tr> </table>									lower	not proven	not quantifiable	minor	considerable	major	Additional benefit (G-BA)						suitable for chemotherapy						not suitable for chemotherapy					
5	4	3b	3a				2c	2b	2a	1b	1a																																																																										
Evidence (LoE)																																																																																					
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;">1</td><td style="width: 20%;">2</td><td style="width: 20%;">3</td><td style="width: 20%;">4</td><td style="width: 20%;">5</td> </tr> <tr> <td colspan="5">Clinical benefit (ESMO MCBS)</td> </tr> </table>									1	2	3	4	5	Clinical benefit (ESMO MCBS)																																																																							
1	2	3	4				5																																																																														
Clinical benefit (ESMO MCBS)																																																																																					
<div style="display: flex; justify-content: space-around;"> ■ curative ■ non-curative </div>																																																																																					
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;">lower</td><td style="width: 20%;">not proven</td><td style="width: 20%;">not quantifiable</td><td style="width: 20%;">minor</td><td style="width: 20%;">considerable</td><td style="width: 20%;">major</td> </tr> <tr> <td colspan="6">Additional benefit (G-BA)</td> </tr> <tr> <td colspan="6">suitable for chemotherapy</td> </tr> <tr> <td colspan="6">not suitable for chemotherapy</td> </tr> </table>									lower	not proven	not quantifiable	minor	considerable	major	Additional benefit (G-BA)						suitable for chemotherapy						not suitable for chemotherapy																																																										
lower	not proven	not quantifiable	minor	considerable	major																																																																																
Additional benefit (G-BA)																																																																																					
suitable for chemotherapy																																																																																					
not suitable for chemotherapy																																																																																					
Remarks: 87% of patients in the control arm received Crizotinib at a later stage (crossover/switching).																																																																																					
Patients	ALK+, after chemotherapy																																																																																				
Trial	PROFILE 1007, phase 3																																																																																				
Randomisation	1 : 1																																																																																				
N¹	347																																																																																				
New Therapy	Crizotinib																																																																																				
Control	Docetaxel or Pemetrexed																																																																																				
Publication	DOI. 10.1056/NEJMoa1214886																																																																																				

Legende:

¹ N - number of patients

² RR - remission rate, in %

³ PFS - progression-free survival in months

⁵ OS - overall survival in months

⁷ SAE - serious adverse events, CTCAE grade 3/4

¹⁴ results for control, results for new therapy

¹⁵ hazard ratio for new therapy

¹⁶ n. s. not significant